Jarden valuation, page-16

Hi Antibotter,

What makes you think this is overvalued - can you please provide some reasoning?

I've seen ASX biotecs trade at a PE ratio of 250.

Not saying Telix will trade at 250 but it's substantially de-risked now that it has an approved product and I'm surprised that it's only trading at a 2 billion dollar market cap.

If Telix can do 37.5 mil of revenue next year through illuccix based on TGA approval (even at a PE of 90) then that should put a valuation of approx 3.4 billion vs 2 billion currently.

That also discounts illuccix approval in all other territories that they currently have applications in. It also discounts approval of any other products.

Also, most of the companies that Telix are collaborating with have huge market caps. Even just look at the Amgen collaboration. They have a market cap of 124 US billion. They could do a takeover for 10 billion in a blink of an eye.

I really think this is just the beginning and I think the funds know it too.